Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Acaster Lloyd Consulting Ltd., London, UK.
BMC Res Notes. 2022 Aug 8;15(1):273. doi: 10.1186/s13104-022-06161-6.
This research sought to explore health care providers' (HCPs) experiences of delivering the first US Food and Drug Administration (FDA) and European Commission (EC) approved peanut oral immunotherapy (peanut OIT; Palforzia). Semi-structured qualitative interviews with HCPs who had initiated treatment with ≥ 3 patients in the first nine months following FDA approval sought to identify challenges faced and successful implementation strategies.
Eight allergists and three nurse practitioners from eight sites based in the United States participated. The HCPs included in this research were motivated to implement this novel treatment, however, entered the process with some reservations. HCPs described how successful implementation of peanut OIT requires them to be thoughtful about their clinic's abilities to integrate complex, time-consuming treatments into their daily practice. Prior experience of OIT was deemed beneficial, but not essential for implementation and learning from others' experience was suggested as a way of helping new prescribers overcome perceived and actual implementation challenges. Delivering licensed peanut OIT during the COVID-19 pandemic posed both challenges and unexpected opportunities for implementation. The experiences described have the potential to benefit the wider allergy community by providing practical solutions, successful implementation strategies and opportunities to enhance training and resources.
本研究旨在探讨医疗保健提供者（HCP）在使用首个获得美国食品和药物管理局（FDA）和欧洲委员会（EC）批准的花生口服免疫疗法（peanut OIT；Palforzia）时的经验。对在 FDA 批准后前九个月内为≥3 名患者开始治疗的 HCP 进行半结构化定性访谈，以确定所面临的挑战和成功的实施策略。
来自美国 8 个地点的 8 名过敏专家和 3 名护士从业者参与了这项研究。参与这项研究的 HCP 有动力实施这种新的治疗方法，但对其实施过程持保留意见。HCP 描述了成功实施花生 OIT 需要他们仔细考虑诊所将复杂且耗时的治疗融入日常实践的能力。先前的 OIT 经验被认为是有益的，但不是实施的必要条件，从他人的经验中学习被认为是帮助新处方者克服感知和实际实施挑战的一种方式。在 COVID-19 大流行期间提供许可的花生 OIT 给实施带来了挑战和意外的机会。所描述的经验有可能通过提供实用的解决方案、成功的实施策略以及增强培训和资源的机会，使更广泛的过敏社区受益。
